CXCR2 and non-Hodgkin lymphoma: A population-based case-control study, conducted in patients with non-Hodgkin lymphoma and in healthy individuals, showed that CXCR2 rs1126580, as well as IL1A rs1800587, TNF rs1800629, and IL4R rs2107356 polymorphisms, were the strongest predictors of the overall survival (OS) in the patients with DLBCL [41].